An Open-Label Multiple Dose Study of RZ358 in Patients With Congenital Hyperinsulinism

Overview

The objective of this trial is to evaluate the safety, tolerability and glucose-raising effects of RZ358 in patients with Congenital Hyperinsulinism (HI).

Full Title of Study: “An Open-Label Multiple-Dose Study of RZ358 in Patients With Congenital Hyperinsulinism”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Non-Randomized
    • Intervention Model: Sequential Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: April 5, 2022

Detailed Description

There is a significant unmet medical need to develop new therapies aimed at preventing chronic recurrent hypoglycemia in congenital HI, the most common cause of persistent hypoglycemia in children. RZ358 is a human mAb that allosterically attenuates excessive insulin action on target cells. Therefore, RZ358 is ideally suited as a potential therapy for hyperinsulinism, and it is being developed to treat the hypoglycemia associated with diseases such as congenital HI. This is a Phase 2, multicenter, open label clinical study designed to assess the safety and efficacy of four progressively higher doses of RZ358 in separate groups of patients with hyperinsulinemic hypoglycemia due to Congenital HI, not adequately controlled with or without current standard of care. A screening period of up to 5 weeks will evaluate eligibility. Once enrolled, RZ358 will be administered bi-weekly over 8 weeks, and then patients will complete a post-treatment follow-up period of 13 weeks.

Interventions

  • Drug: RZ358 Sequential Group Cohort 1
    • IV infusion for 8 weeks (3 mg/kg bi-weekly for 8 weeks)
  • Drug: RZ358 Sequential Group Cohort 2
    • IV infusion for 8 weeks (6 mg/kg bi-weekly for 8 weeks)
  • Drug: RZ358 Sequential Group Cohort 3
    • IV infusion for 8 weeks (9 mg/kg bi-weekly for 8 weeks)
  • Drug: RZ358 Sequential Group Cohort 4
    • IV infusion for 8 weeks (bi-weekly fixed dose-titration from 3 to 9 mg/kg for the first 4 weeks, followed by a fixed 9 mg/kg dose amount thereafter for the remaining 4 weeks)

Arms, Groups and Cohorts

  • Experimental: RZ358 Cohort 1
  • Experimental: RZ358 Cohort 2
  • Experimental: RZ358 Cohort 3
  • Experimental: RZ358 Cohort 4

Clinical Trial Outcome Measures

Primary Measures

  • Glycemic efficacy: Target glucose control
    • Time Frame: 8 weeks
    • Change from Baseline in Percent Time in Glucose Target Range by Continuous Glucose Monitor (CGM)
  • Repeat dose safety and tolerability of RZ358
    • Time Frame: Through 21 Weeks
    • Occurrence of a safety signal as assessed by the incidence of treatment-emergent AEs, SAEs, and AEs leading to study drug discontinuation.
  • Repeat dose pharmacokinetics of RZ358
    • Time Frame: Through 8 weeks
    • Change from baseline in RZ358 drug exposure as assessed by Population-PK modeling of maximum concentrations (Cmax) and Area under the Concentration-Time Curve (AUC).

Secondary Measures

  • Glycemic efficacy: Occurrence of hypoglycemia
    • Time Frame: 8 weeks
    • Change from Baseline in the Incidence of Hypoglycemia by Self-Monitored Blood Glucose (SMBG)
  • Glycemic efficacy: Duration of Hypoglycemia
    • Time Frame: 8 weeks
    • Change from Baseline in the Absolute (minutes) and Percent Time with Hypoglycemia by CGM
  • Glycemic efficacy: Occurrence of Hypoglycemia
    • Time Frame: 8 weeks
    • Change from Baseline in the Incidence of Hypoglycemia by CGM
  • Overnight Target Glucose Control
    • Time Frame: 8 weeks
    • Change from Baseline in Percent Time in Overnight (midnight to 8 am) Glucose Target Range by CGM
  • Glycemic Efficacy: Ability to Complete a Fast without Hypoglycemia
    • Time Frame: 8 weeks
    • Change from Baseline in Incidence of Hypoglycemia by SMBG, During a 12-hour Fasting Challenge

Participating in This Clinical Trial

Inclusion Criteria

  • Male or female age 2-45 years old (except age 12-45 in US) with an established clinical diagnosis of congenital hyperinsulinism – Able to provide written informed consent or, as applicable, assent – Confirmed hypoglycemia as assessed by CGM, SMBG, and clinical evaluation, during Screening – Willingness to use contraception if of child-bearing potential Exclusion Criteria:

  • Out of range blood work for study entry – Body Mass index outside of study entry criteria – History of malignancy – Clinically significant diseases, seropositivity for HIV, hepatitis B or C antibody – Use of systemic corticosteroids within 30 days before Screening – Known or suspected allergy to the study drug – Recent use of an investigational drug or treatment, or participation in an investigational study – Pregnant or lactating women – History of drug abuse or excessive alcohol use

Gender Eligibility: All

Minimum Age: 2 Years

Maximum Age: 45 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Rezolute
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.